The Conversation (0)
Provectus Biopharmaceuticals Announces Data on PV-10 and Co-Inhibitory Blockade
Feb. 24, 2016 11:23AM PST
Biotech InvestingProvectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) announced that data on intralesional PV-10 and co-inhibitory blockade in a melanoma model will be presented at the American Association for Cancer Research’s Annual Meeting 2016 on Wednesday, April 20, 2016, from 8 am to 12 Noon Central Standard Time.
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) announced that data on intralesional PV-10 and co-inhibitory blockade in a melanoma model will be presented at the American Association for Cancer Research’s Annual Meeting 2016 on Wednesday, April 20, 2016, from 8 am to 12 Noon Central Standard Time.
According to the news:
The poster presentation is titled, “T Cell Mediated Immunity after Combination Therapy with Intralesional PV-10 and Co-Inhibitory Blockade in a Melanoma Model.” Scheduled for presentation at Section 26 of the exhibition area, the data are from a team of researchers at the H. Lee Moffitt Cancer Center in Tampa, led by Dr. Shari Pilon-Thomas.